Ignite Creation Date:
2025-12-25 @ 1:31 AM
Ignite Modification Date:
2025-12-27 @ 10:48 PM
Study NCT ID:
NCT04675294
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-08-01
First Post:
2020-12-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Sponsor:
ALX Oncology Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-04-02
Start Date Type:
ACTUAL
Primary Completion Date:
2025-03-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2020-12-15
First Submit QC Date:
None
Study First Post Date:
2020-12-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-30
Last Update Post Date:
2025-08-01
Last Update Post Date Type:
ACTUAL